In the next five to ten years, the pharmaceutical industry is expected to appear 10 times or even 50 times the bull stock

In recent years, with the development of China's economy and society, people's consumption level continues to upgrade, the demand for health care also continues to expand, driving China's pharmaceutical market expansion, and the growth rate is obvious, by 2018 has been second only to the United States, China has become the world's second largest pharmaceutical market.
long term, the logic of the long-term development of the pharmaceutical industry remains unchanged, the industry is expected in the next five to ten years, the pharmaceutical industry is expected to appear 10 times, 50 times the bull stock or even 100 times the bull stock.
from the point of view of market demand, the aging of the population, the increasing consumption, health care awareness and other factors will bring about the growth of the pharmaceutical market demand.
other industry pointed out that from the current consumption structure, China's cancer and some of the slow disease field of drug development space is huge, while the demand for professional medical services is also expected to grow.
, the future pharmaceutical market in the total growth, there will also be structural growth momentum.
From the point of view of the drug use structure, in recent years, drug reviews have been increasing rapidly, coupled with the promotion of consistent evaluation and the publication of the list of complementary medications, some of the drugs that were privileged in the past are no longer covered by health insurance or have reduced reimbursement rates.
industry estimates that this portion will save tens of billions of dollars in health care funds to make room for subsequent drugs that truly meet clinical needs and are cost-effective.
understand that before the drug review reform, the global innovative drugs are generally listed overseas 5 to 10 years after the listing in China, health insurance will take another 5 to 10 years.
but now the time it takes for innovative drugs to be approved for sale at home and to get health insurance is getting shorter.
take the lung cancer treatment drug oxytosini, which was approved globally in 2016, was successfully approved at home a year later, and successfully entered health insurance in 2018, bringing good news to lung cancer patients.
from the policy side, consistent evaluation, volume procurement and other policies are forcing the pharmaceutical industry transformation and upgrading, innovative drugs have broad prospects, favored by the industry.
industry believes that listed companies that can continue to create value have a high probability of becoming 10 times or even 50 times the bull stock.
is therefore key for pharmaceutical companies to continue to innovate and create value.
recent years, some companies committed to innovative drug research and development have also increased their research and development investment, such as Hengrui since 2015, its annual research and development investment accounted for more than 10% of sales revenue.
the first three quarters of this year, Hengrui Pharmaceutical's research and development expenses amounted to 3,344 million yuan, up 15.34% year-on-year and accounting for 17.23% of total revenue.
currently in the development of innovative drugs, the company has basically formed an annual application for innovative drugs clinical, every 1-2 years there is a benign development trend of innovative drugs on the market.
present, the company's innovative drugs are erytheb, thiopental non-gesting, pyrigotinib, carelli pearl monoanti and toluene sulfonate remathram and other products have been approved for market.
addition, with the domestic pharmaceutical entrepreneurship environment to improve, more and more overseas talents emerged to return to the tide, through the return to set up innovative pharmaceutical companies or join the domestic development prospects of the company.
For example, recent news, Dr. Liu Yongjun, who has worked for several large multinational pharmaceutical companies such as Sanofi, joined Cynda Bio Appointed Group President and will be responsible for the Group's global research and development, pipeline strategy, business cooperation and international business;
background, the fast-growing Chinese pharmaceutical market is becoming the next stop for multinational pharmaceutical companies.
the support and efforts of these talented people, I believe that in 5 to 10 years, domestic enterprises can make an impact on the global market "big medicine" for the benefit of the vast number of patients.